NantHealth (NH) Raised to Hold at BidaskClub

NantHealth (NASDAQ:NH) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

Several other analysts have also recently commented on NH. Jefferies Group reiterated a “buy” rating and issued a $5.00 price objective on shares of NantHealth in a research note on Thursday, September 28th. Zacks Investment Research upgraded shares of NantHealth from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research note on Thursday, October 12th. Finally, Canaccord Genuity reduced their price objective on shares of NantHealth from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, November 17th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $8.05.

NantHealth (NH) traded up $0.18 during mid-day trading on Tuesday, hitting $3.95. 526,800 shares of the stock traded hands, compared to its average volume of 225,050. NantHealth has a one year low of $2.60 and a one year high of $10.02. The firm has a market cap of $427.90 and a PE ratio of -2.71. The company has a debt-to-equity ratio of 0.93, a current ratio of 2.38 and a quick ratio of 2.36.

NantHealth (NASDAQ:NH) last released its earnings results on Thursday, November 9th. The company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. NantHealth had a negative net margin of 225.76% and a negative return on equity of 46.09%. The company had revenue of $21.76 million during the quarter, compared to analysts’ expectations of $29.42 million. During the same quarter last year, the business earned ($0.18) EPS. The business’s revenue was up 5.3% on a year-over-year basis. equities research analysts forecast that NantHealth will post -1.35 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP purchased a new position in NantHealth during the 3rd quarter valued at about $365,000. Northern Trust Corp increased its holdings in NantHealth by 133.9% during the 2nd quarter. Northern Trust Corp now owns 151,907 shares of the company’s stock valued at $643,000 after acquiring an additional 86,955 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in NantHealth by 91.5% during the 2nd quarter. Goldman Sachs Group Inc. now owns 169,603 shares of the company’s stock valued at $717,000 after acquiring an additional 81,024 shares in the last quarter. Vanguard Group Inc. increased its holdings in NantHealth by 20.2% during the 2nd quarter. Vanguard Group Inc. now owns 423,537 shares of the company’s stock valued at $1,792,000 after acquiring an additional 71,087 shares in the last quarter. Finally, State Street Corp increased its holdings in NantHealth by 88.1% during the 2nd quarter. State Street Corp now owns 147,234 shares of the company’s stock valued at $623,000 after acquiring an additional 68,963 shares in the last quarter. Hedge funds and other institutional investors own 7.10% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.com-unik.info/2018/01/16/nanthealth-nh-raised-to-hold-at-bidaskclub.html.

About NantHealth

NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.

Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit